Format

Send to

Choose Destination
Eur Urol. 2014 Dec;66(6):1109-15. doi: 10.1016/j.eururo.2014.08.011. Epub 2014 Aug 26.

The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

Author information

1
Department of Public Health, Erasmus Medical Centre, Rotterdam, The Netherlands. Electronic address: m.vedder@erasmusmc.nl.
2
Department of Public Health, Erasmus Medical Centre, Rotterdam, The Netherlands.
3
Departments of Surgery (Urology), Laboratory Medicine, and Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK; Department of Laboratory Medicine and Clinical Sciences in Malmö, Lund University, Skåne University Hospital, Malmö, Sweden; Institute of Biomedical Technology, University of Tampere, Tampere, Finland.
4
Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
5
Department of Pathology, Erasmus Medical Centre, Rotterdam, The Netherlands.
6
Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands.

Abstract

BACKGROUND:

Prostate-specific antigen (PSA) testing has limited accuracy for the early detection of prostate cancer (PCa).

OBJECTIVE:

To assess the value added by percentage of free to total PSA (%fPSA), prostate cancer antigen 3 (PCA3), and a kallikrein panel (4k-panel) to the European Randomised Study of Screening for Prostate Cancer (ERSPC) multivariable prediction models: risk calculator (RC) 4, including transrectal ultrasound, and RC 4 plus digital rectal examination (4+DRE) for prescreened men.

DESIGN, SETTING, AND PARTICIPANTS:

Participants were invited for rescreening between October 2007 and February 2009 within the Dutch part of the ERSPC study. Biopsies were taken in men with a PSA level ≥3.0 ng/ml or a PCA3 score ≥10. Additional analyses of the 4k-panel were done on serum samples.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:

Outcome was defined as PCa detectable by sextant biopsy. Receiver operating characteristic curve and decision curve analyses were performed to compare the predictive capabilities of %fPSA, PCA3, 4k-panel, the ERSPC RCs, and their combinations in logistic regression models.

RESULTS AND LIMITATIONS:

PCa was detected in 119 of 708 men. The %fPSA did not perform better univariately or added to the RCs compared with the RCs alone. In 202 men with an elevated PSA, the 4k-panel discriminated better than PCA3 when modelled univariately (area under the curve [AUC]: 0.78 vs. 0.62; p=0.01). The multivariable models with PCA3 or the 4k-panel were equivalent (AUC: 0.80 for RC 4+DRE). In the total population, PCA3 discriminated better than the 4k-panel (univariate AUC: 0.63 vs. 0.56; p=0.05). There was no statistically significant difference between the multivariable model with PCA3 (AUC: 0.73) versus the model with the 4k-panel (AUC: 0.71; p=0.18). The multivariable model with PCA3 performed better than the reference model (0.73 vs. 0.70; p=0.02). Decision curves confirmed these patterns, although numbers were small.

CONCLUSIONS:

Both PCA3 and, to a lesser extent, a 4k-panel have added value to the DRE-based ERSPC RC in detecting PCa in prescreened men.

PATIENT SUMMARY:

We studied the added value of novel biomarkers to previously developed risk prediction models for prostate cancer. We found that inclusion of these biomarkers resulted in an increase in predictive ability.

KEYWORDS:

Kallikrein panel (4k-panel); Percentage of free to total PSA; Prostate biopsy; Prostate cancer; Prostate cancer antigen 3 (PCA3); Prostate cancer risk calculator; Validation

PMID:
25168616
PMCID:
PMC4407822
DOI:
10.1016/j.eururo.2014.08.011
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center